ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

GDRX GoodRx Holdings Inc

7.01
-0.07 (-0.99%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
GoodRx Holdings Inc NASDAQ:GDRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.07 -0.99% 7.01 7.00 7.60 7.35 7.09 7.27 938,229 00:59:02

Statement of Changes in Beneficial Ownership (4)

13/07/2021 12:02am

Edgar (US Regulatory)


FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Azad Babak
2. Issuer Name and Ticker or Trading Symbol

GoodRx Holdings, Inc. [ GDRX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
See Remarks
(Last)          (First)          (Middle)

C/O GOODRX HOLDINGS, INC., 2701 OLYMPIC BOULEVARD
3. Date of Earliest Transaction (MM/DD/YYYY)

7/9/2021
(Street)

SANTA MONICA, CA 90404
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 7/9/2021  M  12500 A$5.94 12500 D  
Class A Common Stock 7/9/2021  S(1)  12500 D$32.9806 (2)0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $5.94 7/9/2021  M     12500   (3)1/30/2030 Class A Common Stock 12500 $0.00 337500 D  

Explanation of Responses:
(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into as of December 9, 2020.
(2) This price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.42 to $33.30. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(3) The option has vested and became exercisable or will vest and become exercisable with respect to the original 600,000 underlying shares of Class A common stock in equal monthly installments over a four year period that commenced on October 9, 2019.

Remarks:
Remarks: Chief Marketing Officer and SVP, Marketing & Communications

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Azad Babak
C/O GOODRX HOLDINGS, INC.
2701 OLYMPIC BOULEVARD
SANTA MONICA, CA 90404


See Remarks

Signatures
/s/ Gracye Cheng, as Attorney-in-Fact for Babak Azad7/12/2021
**Signature of Reporting PersonDate

1 Year GoodRx Chart

1 Year GoodRx Chart

1 Month GoodRx Chart

1 Month GoodRx Chart

Your Recent History

Delayed Upgrade Clock